Ricardo Garcia: Dovitinib has received Orphan Drug Designation (ODD) from the FDA for osteosarcoma.
Ricardo Garcia, CEO and founder of Oncoheroes Biosciences, posted on his LinkedIn page:
“Here we go again! Just a few days ago, we were thrilled to share the FDA’s green light to allow us to proceed with the clinical trials of two of our potential drugs for pediatric oncology, Volasertib and Dovitinib. Today, we have even more reasons to celebrate as we proudly announce a significant achievement: Dovitinib has received Orphan Drug Designation (ODD) from the FDA for its promising role in combating osteosarcoma, a recognition previously bestowed upon Volasertib.
Our tireless commitment to pioneering groundbreaking treatments is yielding remarkable results. Both Volasertib and Dovitinib have also earned Rare Pediatric Disease Designation from the FDA, an honor that extends their eligibility for Priority Review Vouchers (PRV). For those who may not be familiar with PRVs, they are invaluable incentives for the development of pediatric cancer drugs.
Our journey is far from over, and we are immensely grateful for everyone supporting our mission in one way or another.
Onwards!”
Source: Ricardo Garcia/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023